# Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

> **NCT04698941** · PHASE2 · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 40 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Albumin Paclitaxel
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT04698941
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-25
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04698941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04698941, "Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04698941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*